Researchers tested the molecule’s impact on both bone cells and immune cells. During their experiments, the team discovered metal particles coming from the implants accelerate the progression of bone resorption. However, in animal tests, study authors found SNV could suppress this resorption. Therefore, the new drug shows great promise at preserving the hold joint implants and teeth have in the surrounding bone tissue.
“This project is a classic example of collaboration between different departments at TAU’s Faculty of Medicine,” says Prof. Yankel Gabet.
“On the one hand, together with Prof. David Kohavi, my group has for years studied the connection between the immune system, inflammatory response, and bone cells. On the other, Dr. Michal Eger is a dentist who decided to explore these processes for her doctoral thesis. She attended a course given by Prof. Gozes, in which VIP and SNV were discussed, and an in-depth conversation led to the idea of checking whether these molecules can prevent bone loss around implants and natural teeth. We quickly discovered the enormous potential of SNV for people who suffer from bone loss around teeth and implants. Currently we are working on translating this new discovery to the clinic.”